Government Grant	6 Months Ended
Jun. 30, 2022
Government Grants [Abstract]
Government Grant	9. Government Grant In September 2019, the Company was awarded a two-year $1.0 million grant from the orphan drug office of the U.S. Food and Drug Administration to support the clinical development of TAVNEOS in patients with the rare kidney disease complement 3 glomerulopathy (C3G). The grant was extended for an additional four months in August 2021 and the grant revenue was fully recognized in 2021. Accordingly, no revenue was recognized during the three and six months ended June 30, 2022 compared to $0.1 million and $0.2 million in the same periods of 2021. As of June 30, 2022 and December 31, 2021, $0 and $28,000 was recorded as accounts receivable, respectively.

Government Grant

6 Months Ended

Jun. 30, 2022

In September 2019, the Company was awarded a two-year $1.0 million grant from the orphan drug office of the U.S. Food and Drug Administration to support the clinical development of TAVNEOS in patients with the rare kidney disease complement 3 glomerulopathy (C3G). The grant was extended for an additional four months in August 2021 and the grant revenue was fully recognized in 2021. Accordingly, no revenue was recognized during the three and six months ended June 30, 2022 compared to $0.1 million and $0.2 million in the same periods of 2021. As of June 30, 2022 and December 31, 2021, $0 and $28,000 was recorded as accounts receivable, respectively.